https://orcid.org/0000-0002-8369-5447
References
- Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–298.
- Kline TS, Joshi LP, Neal HS. Fine-needle aspiration of the breast: diagnoses and pitfalls. A review of 3545 cases. Cancer. 1979;44(4):1458–1464.
- Willems SM, van Deurzen CH, van Diest PJ. Diagnosis of breast lesions: fine-needle aspiration cytology or core needle biopsy? A review. J Clin Pathol. 2012;65(4):287–292.
- Kataja V, Castiglione M, Group EGW. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):10–14.
- Gradishar W, Anderson BO, Abraham J, et al. NCCN guidelines: breast cancer, version 2.2019. Huntington, NY: National Comprehensive Cancer Network; 2019.
- Nortier JWR, Rutgers EJT, Sangen van der MJC, et al. Dutch multidisciplinary breast cancer guideline ('Richtlijn Mammacarcinoom'). Amsterdam: NABON. Available from: http://www.oncoline.nl/mammacarcinoom2012
- Quality standard [QS12]: breast cancer: National Institute for Health and Care Excellence; 2016. Available from: https://www.nice.org.uk/guidance/qs12
- Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19–24.
- Bulte JP, Polman L, Schlooz-Vries M, et al. One-day core needle biopsy in a breast clinic: 4 years experience. Breast Cancer Res Treat. 2013;137(2):609–616.
- Nederend J, Duijm LE, Louwman MW, et al. Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study. Ann Oncol. 2012;23(12):3098–3103.
- Herold CI, Marcom PK. Primary systemic therapy in breast cancer: past lessons and new approaches. Cancer Invest. 2008;26(10):1052–1059.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
- Mammacarcinoom: screening en diagnostiek. Utrecht: kwaliteitsinstituut voor de gezondheidszorg CBO; 2020.
- Richtlijn mammacarcinoom. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO; 2020.
- Het resultaat telt. Prestatie-indicatoren als onafhankelijke graadmeter voor de kwaliteit van in ziekenhuizen verleende zorg. Health Care Inspectorate (IGZ); 2004; [cited 2019 Jun 4]. Available from: https://www.medischcontact.nl/web/file?uuid=5ed1e4cf-82bd-4f06-8f7d-5d98ff842947&owner=1e836119-cfd1-4e33-a731-da3efbb2a701&contentid=53692
- van Breest Smallenburg V, Nederend J, Voogd AC, et al. Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands. Br J Cancer. 2013;109(1):242–248.
- Neuner JM, Nattinger AB, Yen T, et al. Temporal trends and regional variation in the utilization of low-value breast cancer care: has the choosing wisely campaign made a difference? Breast Cancer Res Treat. 2019;176(1):205–215.